Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522558 | 1.00 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL20612426 | 0.89 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16466450 | 0.89 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16465286 | 0.89 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8251750 | 0.86 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| Valine SCHEMBL8913982 | 0.86 | SMN1; SMN2 (0.55) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL7469804 | 0.86 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL3325041 | 0.86 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16408319 | 0.85 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL4970964 | 0.85 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417128-B1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-02 | — | — | EP | disclosed |
| US-8288385-B2 | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-2417128-A2 | 6-(3-AZA-BICYCLOÝ3.1.0¨HEX-3-YL)-2-PHENYL-PYRIMIDINES | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| WO-2010116328-A2 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | P2RY12, P2RY13, P2RY6 | MEN1 4360/4885KMT2A 3240/4885NPSR1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.